CDKN2A and neoplasm: Of the four putative tumor suppressors, CSMD3 has a disputed cancer role [39–41] and a likely inflated mutation rate [42], while CDKN2B cooperates with its paralog CDKN2A to inhibit cell cycle [43], supporting its tumor suppressor role.